Alixorexton
Small molecule
Also known as ALKS 2680
Evidence outlook · registrational
Narcolepsy: registrational readout pending
Its supporting mid-stage studies have completed. Registrational readout expected around 2027-05. The sponsor reported topline results of a Phase 2 study on 2025-11-12 (Phase 2 Vibrance-2 (NCT06555783) met its dual primary endpoints in narcolepsy type 2); that is not the registrational readout.
Also in development:Idiopathic Hypersomnia · Phase 2/3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
Brilliance NT2 NCT07502443 · Narcolepsy Registry: NCT07502443 | 3 | Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level 2027-05 | In progress: results expected 1 May 2027 | not yet graded | link ↗ |
View 2 more trials
Brilliance NT1 NCT07455383 · Narcolepsy Registry: NCT07455383 | 3 | Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level 2027-05 | In progress: results expected 1 May 2027 | not yet graded | link ↗ |
NCT07540897 NCT07540897 · Narcolepsy Registry: NCT07540897 | 3 | Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level 2027-06 | In progress: results expected 1 Jun 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other Orexin-2 receptor (agonist) drugs
Oveporexton, TAK-360. Compare all 3 Orexin-2 receptor (agonist) drugs
2 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Idiopathic Hypersomnia: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Alixorexton: this drug | Phase 2/3 | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Calcium, Magnesium, Potassium And Sodium Oxybates (Xywav) | Approved | Small molecule | GABA-B receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Pitolisant (Wakix) | Phase 3 | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Alixorexton to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
What to watch
2027 (3)
May 2027 (2)
June 2027 (1)
2030 (1)
June 2030 (1)
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent